Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001957934 | SCV002216187 | uncertain significance | Nephronophthisis | 2021-11-26 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 1090 of the NPHP4 protein (p.Ala1090Thr). This variant is present in population databases (rs573269001, gnomAD 0.004%). This variant has not been reported in the literature in individuals affected with NPHP4-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The threonine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002479520 | SCV002789607 | uncertain significance | Nephronophthisis 4; Senior-Loken syndrome 4 | 2024-06-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002562169 | SCV003596819 | uncertain significance | Inborn genetic diseases | 2022-01-18 | criteria provided, single submitter | clinical testing | The c.3268G>A (p.A1090T) alteration is located in exon 23 (coding exon 22) of the NPHP4 gene. This alteration results from a G to A substitution at nucleotide position 3268, causing the alanine (A) at amino acid position 1090 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |